We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPPIX.L Regulatory News (PPIX)

  • There is currently no data for PPIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ProPhotonix issues Half-year Report

6 Sep 2019 07:00

RNS Number : 4318L
ProPhotonix Limited
06 September 2019
 

 

September 6, 2019

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

ProPhotonix Limited

 ("ProPhotonix" or "the Company")

 

INTERIM RESULTS FOR THE HALF YEAR ENDED JUNE 30, 2019

 

ProPhotonix Limited (London Stock Exchange - AIM: PPIX & PPIR, OTC: STKR), a high technology designer and manufacturer of LED illumination systems and laser diode modules, with operations in Ireland and the United Kingdom, today announces its unaudited interim results for the six months ended June 30, 2019.

 

Financial Highlights

·; Revenue decreased 18.9% to $7.2 million (H1-2018: $8.8 million)

·; Gross profit decreased 21.7% to $2.7 million (H1-2018: $3.4 million) mainly due to decreased revenue

·; Operating loss (excluding stock compensation credit $0.5 million) of $0.6 million (H1-2018: $0.1 million operating income, excluding stock compensation expense $0.5 million)

·; Net loss of $0.2 million (H1-2018: $0.5 million)

·; Adjusted EBITDA of $(0.5) million (H1-2018: $0.2 million). Please see the reconciliation of net loss to adjusted EBITDA below.

·; Order bookings of $7.5 million (H1-2018: $9.0 million)

·; Book-to-Bill ratio of 1.04 (H1-2018: 1.03)

·; Percentage revenue by market sectors: 73% industrial, 23% medical and 4% security & defense (H1-2018: 81% industrial, 16% medical and 3% security & defense)

·; Percentage revenue by geography: 40% Europe, 58% North America and 2% Rest of World (H1-2018: 56% Europe, 31% North America and 13% Rest of World)

 

 

 

 

Tim Losik, President & CEO, commented:

 

Financial

 

"Revenues in the first half of 2019 were down 18.9% primarily due to a decrease in Laser & Diode product sales (including the decline of $0.9 million from the largest customer due to a delay in a new product launch) partially offset by a small net increase in LED product sales. Gross profit margin fell to 37.2% compared with 38.6% for the same period in 2018, mainly due to a shift in product mix and under absorption of manufacturing overhead on lower sales. In the first half of 2019 we experienced an operating loss of $0.1 million compared to operating loss of $0.4 million in 2018. The operating loss was primarily a result of lower profit margins and continued investment to support future growth of the business, offset by a credit of stock compensation of $0.5 million for 2019 (1H 2018 - expense $0.5 million). During the first half, cost reduction measures were put in place to lower the cost structure by about $0.3 million per annum.

 

The cash position of the Company has reduced due to operating losses incurred and will likely continue, though at a slower rate as the cost reduction measures take effect, through the balance of the year. The Directors are investigating securing new sources of capital as well as other strategic initiatives and options."

 

Trading update and Strategic Review

 

"Decreased revenue has occurred in nearly half of 2018 customers offset by increases in about 25% of customers, albeit we take some reassurance that during the first half our largest laser customer and several large LED customers resumed and/or increased both the volume and value of orders placed with Prophotonix. Overall however, the volume of orders were down 17% in the half despite these customers increasing orders, and continue to be sluggish early in the second half. Currently, we are not able to accurately estimate full year sales, but the Board currently envisage they will be no more than $15.0 million.

 

 

 "As noted above, we are now forecasting revenues in the second half will broadly approximate those achieved in the first half. Whilst we expect to see the financial benefit of the cost savings initiatives enacted in the first half, the Board believes the Company will continue to be loss making and is committed to strengthening the Group's balance sheet. The Board is therefore reviewing all funding and strategic options available, both to ensure the short-term working capital needs of the Company continue to be met, as well as maximizing shareholder value over the longer term."

 

Enquiries:

 

ProPhotonix Limited

Tim Losik, President & CEO

Tel: +1 603 893 8778

ir@prophotonix.com

 

Cantor Fitzgerald Europe

(Nominated Adviser and Broker) Tel: +44 (0)207 894 7000

David Foreman (Corporate Finance)

Keith Dowsing (Equity Sales)

 

 

 

Half Year 2019 Financial Results

 

Revenue for the half year ended June 30, 2019 was $7.2 million, a decrease of 18.9% compared with $8.8 million in the same period of 2018 primarily due to a decrease in Laser & Diode product sales (including the decline of $0.9 million from the largest customer due to a delay in a new product launch) partially offset by a small net increase in LED product sales. Revenue by industry category shifted with medical increasing due to the commercialization of products for one customer which have been in development. The changes between industrial and defense relate to general shifts in the mix of business rather than any discernible trend. The Group's revenues are not geographically dependent and whilst additional sales were generated in the United States during the period, similar to the changes in mix of business there is no pertinent reason for this change in geographical revenue mix.

 

 

Gross profit was $2.7 million, a decrease of 21.7% compared to $3.4 million in the first half of 2018 from the decline in revenue. Gross profit margin fell to 37.2% compared with 38.6% for the same period in 2018, mainly due to a shift in product mix and under absorption of manufacturing overhead expenses.

 

Operating expenses totaled $2.8 million versus $3.8 million for the comparable period. Sales and marketing expenses decreased $0.3 million to $1.1 million primarily due to decreased stock compensation. General and administrative expenses decreased $0.9 million to $1.1 million primarily due to decreased stock compensation. Research and development expenses remained relatively flat compared with the prior year at $0.6 million.

 

The reduced gross profit resulted in an operating loss of $0.1 million ($0.5 million loss excluding stock compensation credit), compared with an operating loss of $0.4 million in the first half of 2018 ($0.1 million income excluding stock compensation expense).

 

Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, stock-based compensation and impairment charges) was a loss of $0.5 million, as compared to a profit of $0.2 million in the first half of 2018. Please see the reconciliation of net income to adjusted EBITDA below.

 

Net loss was $0.2 million, as compared to $0.5 million of net loss in the first half 2018.

 

Net assets decreased by $1.4 million (13%) primarily attributable to net cash outflows of $1.4 million. As of June 30, 2019, the Company held a net debt position of $0.3 million versus a net cash position as of June 30, 2018 of $0.4 million. As of June 30, 2019, the Company had $0.1 million borrowing availability on its Sales Finance facility through Barclays Bank.

 

 

PROPHOTONIX LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF Income AND COMPREHENSIVE INCOME

In thousands except share and per share data

(unaudited)

 

 

 

 

 

Six Months EndedJune 30,

 

2019

 

2018

 

 

Revenue

$ 7,165

$ 8,839

Cost of sales

(4,497)

(5,431)

 

 

 

Gross profit

2,668

3,408

 

 

 

Operating expenses:

 

 

Selling expenses

(1,075)

(1,363)

General and administrative

(1,117)

(2,063)

Research and development

(603)

(414)

 

 

 

Total operating expenses

(2,795)

(3,840)

 

 

 

Loss from operations

(127)

(432)

Other (expense) income, net

(16)

(54)

Interest expense

(55)

(21)

Amortization of debt discount and financing costs

(8)

-

 

 

 

Loss before income tax

(206)

(507)

Income tax

-

-

 

 

 

Net loss

(206)

(507)

Other comprehensive income:

 

 

Foreign currency translation

73

(42)

 

 

 

Total comprehensive loss

$ (133)

$ (549)

 

 

 

 

 

 

 

 

 

Net loss per share:

 

 

Basic net loss per share

$ (0.002)

$ (0.005)

 

 

 

Diluted net loss per share

$ (0.002)

$ (0.005)

 

 

 

 

 

 

 Shares used in per share calculation - basic

93,075

93,000

Shares used in per share calculation - diluted

93,075

93,000

 

 

 

 

 

 

 

 

FINANCIAL STATEMENTS

PROPHOTONIX LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS

In thousands except share and per share data

(unaudited)

 

 

 

 

 

For the Periods Ended June 30, 2019 and 2018

 

2019

 

2018

 

 

 

 

Assets

 

 

Current assets:

 

 

Cash and cash equivalents

$ 1,615

$ 3,033

Accounts receivable, less allowances of $53 in 2019 and $52 in 2018

3,120

3,159

Inventories

2,953

2,761

Prepaid expenses and other current assets

383

439

 

 

 

Total current assets

8,071

9,392

Net property, plant and equipment

597

738

Goodwill

402

413

Deferred tax asset

451

463

Other long-term assets

427

380

 

 

 

Total assets

$ 9,948

$ 11,386

 

 

 

Liabilities and Stockholders' Equity

 

 

Current liabilities:

 

 

Revolving credit facility

$ 1,107

$ 1,560

Current portion of long-term debt, net

197

181

Accounts payable

2,151

2,051

Accrued expenses

2,214

2,037

Current portion of capital lease

57

100

 

 

 

Total current liabilities

5,726

5,929

Long-term debt, net of debt acquisition charges

478

684

Long-term capital lease obligations, net of current portion

69

122

 

 

 

Total liabilities

6,273

6,735

 

 

 

 

 

 

Stockholders' Equity:

 

 

Common stock, par value $0.001; shares authorized 250,000,000 at June 30, 2019 and at June 30, 2018; 93,150,402 shares issued and outstanding at June 30, 2019 and 93,000,402 at June 30, 2018

93

93

Paid-in capital

113,579

113,531

Accumulated deficit

(110,952 )

(109,945 )

Accumulated other comprehensive income

955

972

 

 

 

Total stockholders' equity

3,675

4,651

 

 

 

Total liabilities and stockholders' equity

$ 9,948

$ 11,386

 

 

 

    

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands

(unaudited)

 

 

 

 

 

Six Months EndedJune 30,

 

2019

 

2018

 

Operations

 

 

Net loss

$ (206)

$ (507)

 

 

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Stock based compensation

(469)

559

Depreciation

103

91

Foreign exchange loss

13

32

Amortization of debt discount and financing costs

8

-

Provision for inventories

103

3

Provision for bad debts

5

38

Other change in assets and liabilities:

 

 

Accounts receivable

(270)

(164)

Inventories

(672)

(561)

Prepaid expenses and other current assets

(96)

(199)

Accounts payable

371

469

Accrued expenses

887

284

Other assets and liabilities

(17)

(142)

 

 

 

Net cash used in operating activities

(240)

(97)

 

 

 

Financing

 

 

Exercise of options and warrants

-

3

Net borrowing (repayment) of revolving credit facility

17

345

Capital lease

(30)

40

Debt issuance costs

-

(42)

Net borrowing (principal repayment) of long-term debt

(120)

865

 

 

 

Net cash (used in) provided by financing activities

(133)

1,211

 

 

 

Investing

 

 

Purchase of plant and equipment

(94)

(201)

 

 

 

Net cash used in investing activities

(94)

(201)

Effect of exchange rate on cash

143

(30)

 

 

 

Net change in cash and equivalents

(324)

883

Cash and equivalents, beginning of period

1,939

2,150

 

 

 

Cash and equivalents, end of period

$ 1,615

$ 3,033

 

 

 

Supplemental disclosure of cash flow information:

 

 

Cash paid for interest

$ 56

$ 21

 

 

 

 

 

 

 

 

 

 

    

 

 

 

 

 

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

 In thousands 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

 

 

 

 

 

Shares

Par $0.001

Paid in Capital

Deferred Compensation

Accumulated Deficit

Accumulated Other Comprehensive Income

Total Stockholders' Equity

 

Balance December 31, 2018

93,000

$93

$114,067

$(19)

($110,746)

$882

$4,277

 

Net loss

-

-

-

-

(206)

-

(206)

 

 

 

 

 

 

 

 

 

 

Translation adjustment

-

-

-

-

-

73

73

 

 

 

 

 

 

 

 

 

 

Deferred compensation

150

0

5

(5)

-

-

0

 

 

 

 

 

 

 

 

 

 

Share based compensation

-

-

(488)

19

-

-

(469)

 

 

 

 

 

 

 

 

 

 

Balance June 30, 2018

93,150

93

$113,584

$(5)

($110,952)

$955

$3,675

                 

 

 

 

Notes to unaudited Interim Results

 

Basis of Presentation

 

The Company financial reports are issued under the recognition and measurement principles of United States Generally Accepted Accounting Principles (GAAP). The accompanying unaudited condensed consolidated financial reports reflect all adjustments of a normal recurring nature necessary for a fair statement of the (i) results of operations and comprehensive loss for the six month periods ended June 30, 2019 and 2018; (ii) the financial position at June 30, 2019 and June 30, 2018; and (iii) the cash flows for the six month period ended June 30, 2019 and 2018. These unaudited interim results are not necessarily indicative of results for a full year or any other interim period. Copies of this announcement are available on the Company's website at www.prophotonix.com.

 

Revenue Recognition

 

Effective January 1, 2018, the Company has recognized revenue under FASB ASC 606, whereby all contracts containing a performance element have been evaluated for the necessity to recognize revenue as the performance obligation is achieved.

 

 

 

 

Cautionary Statement 

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances will be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.

 

 

 

 

Use of Non-GAAP Financial Measures

 

The Company provides non-GAAP financial measures, such as adjusted EBITDA, to complement its consolidated financial statements presented in accordance with GAAP. Non-GAAP financial measures do not have any standardized definition and, therefore, are unlikely to be comparable to similar measures presented by other reporting companies. These non-GAAP financial measures are intended to supplement the user's overall understanding of the Company's current financial and operating performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses, gains and losses that, when excluded from the GAAP results, may provide additional understanding of the Company's core operating results or business performance, which management uses to evaluate financial performance for purposes of planning for future periods. However, these non-GAAP financial measures are not intended to supersede or replace the Company's GAAP results.

 

The Company uses adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, stock-based compensation and impairment charges) as a non-GAAP financial measure in this press release. A reconciliation of net income to adjusted EBITDA for the six months ended June 30, 2019 and 2018 is as follows:

 

 

 

 

In thousands

 

 

Six Months Ended June 30,

 

 

2019

2018

Net loss

$(206)

$(507)

Plus:

 

 

 

Interest and other (income) expense, net

71

75

 

Amortization of debt discount and financing costs

8

-

 

Depreciation and amortization

103

91

 

Stock based compensation

(469)

559

Adjusted EBITDA

$(493)

$218

 

 

 

About ProPhotonix

 

 

ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of diode-based laser modules and LED systems for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio, Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IR LFFVIAIIEIIA
Date   Source Headline
16th Dec 20217:00 amRNSSale of ProPhotonix and cancelation of AIM Listing
17th Nov 20217:00 amRNSNotice of GM
11th Nov 202111:05 amRNSSecond Price Monitoring Extn
11th Nov 202111:00 amRNSPrice Monitoring Extension
11th Nov 20217:00 amRNSProPhotonix Announces Merger Agreement
2nd Nov 20217:00 amRNSProPhotonix Extends COBRA HyperSpec range
14th Sep 20217:00 amRNSProPhotonix announces the new UV COBRA Cure FX4
8th Sep 20217:00 amRNS2021 Half-year Report
9th Jun 20217:00 amRNSPosting of Annual Report and Accounts
2nd Jun 20217:00 amRNSNew Wavelengths added to UVC LED System
25th Mar 20217:00 amRNSResults for the year ended December 31, 2020
26th Jan 20217:00 amRNSNew Hyperspectral COBRA MultiSpec LED Line Light
16th Nov 20202:05 pmRNSSecond Price Monitoring Extn
16th Nov 20202:00 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSAdmission of Shares
10th Nov 20207:00 amRNSProPhotonix introduces 265nm UVC LED Lamp
9th Nov 20204:45 pmRNSResult of AGM and Director / PDMR Shareholdings
9th Oct 20207:00 amRNSPOSTING OF NOTICE OF ANNUAL GENERAL MEETING
8th Oct 20207:00 amRNSNew RGB-IR & RGB-White COBRA MultiSpec Line Lights
7th Oct 20203:07 pmRNSHolding(s) in Company
10th Sep 20207:00 amRNSINTERIM RESULTS FOR HALF YEAR ENDED JUNE 30, 2020
3rd Sep 20204:40 pmRNSSecond Price Monitoring Extn
3rd Sep 20204:35 pmRNSPrice Monitoring Extension
3rd Sep 20202:05 pmRNSSecond Price Monitoring Extn
3rd Sep 20202:00 pmRNSPrice Monitoring Extension
2nd Sep 20207:00 amRNSPROdigii Digital Lasers Range - 5 New Wavelengths
27th Aug 20207:00 amRNSRESULTS FOR THE YEAR ENDED DECEMBER 31, 2019
25th Aug 20201:47 pmRNSNOTICE OF EXTENSION OF RIGHTS PLAN
24th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSChange of Adviser and Director Disclosures
29th Jun 20207:00 amRNSCustom LED Backlight wins VSD Innovators Award
23rd Jun 20207:00 amRNSAccounts Reporting Extension & Trading Update
30th Apr 20207:00 amRNSDirectorate Change
9th Apr 20207:00 amRNSCOVID – 19 and Trading Update
19th Mar 20207:00 amRNS3 Year Framework Product Supply & IP Agreement
16th Mar 20207:00 amRNSProPhotonix - UV LED Water Disinfection
16th Jan 20207:00 amRNSTrading Update 2019
26th Nov 20197:00 amRNSHolding(s) in Company
10th Oct 20197:00 amRNS5-Year Master Purchase Agreement - Fortune 50 CGLM
12th Sep 20197:00 amRNSProPhotonix to Exhibit UV Lamps at Labelexpo 2019
6th Sep 20197:00 amRNSProPhotonix issues Half-year Report
3rd Sep 20197:00 amRNSNew High-Powered Red Laser Diode from Ushio
31st May 201911:59 amRNSProPhotonix Notification of Major Holdings
31st May 201911:58 amRNSProPhotonix Notification of Major Holdings
24th May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
23rd May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
17th May 20197:00 amRNSProPhotonix Announces Trading Update
16th May 20195:58 pmRNSPPIX Announces AGM Results and PDMR Shareholdings
16th May 20197:00 amRNSPPIX Offers New COBRA Cure Mini UV Curing System
9th Apr 20197:00 amRNSProPhotonix Honored by Vision Systems Design 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.